Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Stroke

被引：9
|
作者：
Kimura, Genjiro [1 ]
机构：
[1] Japan Org Occupat Hlth & Safety, Asahi Rosai Hosp, Hirako Cho North 61, Owariasahi 4888585, Japan
来源：
CIRCULATION JOURNAL | 2017年 / 81卷 / 06期
关键词：
CARDIOVASCULAR OUTCOMES; EMPAGLIFLOZIN; DISEASE;
D O I：
10.1253/circj.CJ-17-0040
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：898 / 898
页数：1
相关论文
共 50 条
  • [21] Sodium-Glucose Cotransporter 2 Inhibitors
    Erol, Cetin
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2024, 28 (05): : 216 - 216
  • [22] Sodium-glucose cotransporter 2 (SGLT2) inhibitors in nephrolithiasis: should we "gliflozin" patients with kidney stone disease?
    de Carvalho, Mauricio
    Heilberg, Ita Pfeferman
    JORNAL BRASILEIRO DE NEFROLOGIA, 2024, 46 (03):
  • [23] The role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in epicardial adipose tissue modulation: a meta-analysis
    Theofilis, P.
    Vlachakis, P. K.
    Antonopoulos, A. S.
    Sagris, M.
    Mantzouranis, E.
    Sakalidis, A.
    Oikonomou, E.
    Siasos, G.
    Tsioufis, K.
    Tousoulis, D.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [24] Sodium-glucose cotransporter 2 (SGLT2) inhibitors-induced erythropoiesis and cardiovascular events in chronic kidney patients
    Marques Vidas, Maria De San Miguel
    Lopez, Paula
    Sanchez Briales, Paula
    Sanchez, Ana
    Lopez Illazquez, Maria Victoria
    Maria Portoles, Jose
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I1043 - I1043
  • [25] Can the Combination of Incretin Agents and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Reconcile the Yin and Yang of Glucagon?
    Goldenberg, Ronald M.
    Verma, Subodh
    Perkins, Bruce A.
    Gilbert, Jeremy D.
    Zinman, Bernard
    CANADIAN JOURNAL OF DIABETES, 2017, 41 (01) : 6 - 9
  • [26] Severe acute complications by sodium-glucose cotransporter-2 (sglt2) inhibitors: A real problem and not so infrecuent
    Trastoy, Olaia Diaz
    Sobrino, Paula Sanchez
    Iraeta, Antonia Lourdes Rego
    MEDICINA CLINICA, 2020, 155 (03): : 138 - 139
  • [27] Sodium-glucose cotransporter 2 (SGLT2) inhibitors-induced erythropoiesis and cardiovascular events in chronic kidney patients
    Vidas, Maria De San Miguel Marques
    Lopez, Paula
    Briales, Paula Sanchez
    Sanchez, Ana
    Illazquez, Maria Victoria Lopez
    Portoles, Jose Maria
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [28] Direct effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on cardiomyocyte function as a potential therapy for Phospholamban cardiomyopathy
    Hnatiuk, Anna
    Li, Alexander
    Staudt, David
    Serrano, Ricardo
    Mercola, Mark
    CIRCULATION RESEARCH, 2024, 135
  • [29] Prevention of cardiovascular disease and renal failure in type 2 diabetes: sodium-glucose cotransporter-2 (SGLT2) inhibitors
    O'Sullivan, Jack W.
    BMJ EVIDENCE-BASED MEDICINE, 2020, 25 (02) : 79 - 80
  • [30] Sodium-glucose cotransporter 2 inhibitors (SGLT2i): renal implications
    Alejandrina M. Castañeda
    Amanda Dutra-Rufato
    Maria J. Juarez
    Luis Grosembacher
    Henry Gonzalez-Torres
    Carlos G. Musso
    International Urology and Nephrology, 2021, 53 : 291 - 299
12345